Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biodexa Pharmaceuticals PLC BDRX

Healthcare Biotechnology
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing... see more

Recent & Breaking News (NDAQ:BDRX)

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

GlobeNewswire 11 days ago

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa(TM) in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

GlobeNewswire 12 days ago

Posting of Annual Report & Notice of AGM - Total Voting Rights

GlobeNewswire May 15, 2024

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Accesswire May 9, 2024

Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa(TM) in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

GlobeNewswire April 30, 2024

Biodexa Enters Into Exclusive License to eRapa(TM), a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

GlobeNewswire April 26, 2024

Preliminary Results for the Year Ended 31 December 2023

GlobeNewswire April 19, 2024

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Accesswire March 28, 2024

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Accesswire March 1, 2024

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

GlobeNewswire February 23, 2024

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

GlobeNewswire February 8, 2024

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

GlobeNewswire February 7, 2024

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

GlobeNewswire January 22, 2024

Biodexa Appoints Ann Merchant to the Board of Directors

GlobeNewswire December 29, 2023

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

GlobeNewswire December 21, 2023

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

GlobeNewswire December 19, 2023

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes

GlobeNewswire November 27, 2023

Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma

GlobeNewswire October 3, 2023

Interim results for the six months ended 30 June 2023

GlobeNewswire September 29, 2023

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

GlobeNewswire September 21, 2023